Tirzepatide Sales Forecast, and Market Size Analysis - 2034
상품코드:1855042
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
Tirzepatide의 성장을 촉진하는 주요 요인들
1. 시장 점유율 확대 및 신규 환자 확보
티르제파타이드는 제2형 당뇨병과 비만 치료에서 빠르게 시장 점유율을 확보하며 최근 가장 성공적인 신약 중 하나로 부상하고 있습니다.
신규 환자 수가 급증하고, 당뇨병 및 비만 치료 의료진의 높은 수요로 인해 처방이 크게 증가하고 있습니다.
일라이 릴리의 적극적인 상업적 전략, 강력한 의사 교육 활동, 소비자 직접 홍보를 통해 치료 분야 전반에 걸쳐 폭넓은 채택을 촉진하고 있습니다.
2. 주요 적응증으로 확대
제2형 당뇨병(Mounjaro) : 주 1회 투여하는 GLP-1/GIP 이중 작용제로 승인되었으며, 기존 GLP-1 치료제 대비 HbA1c 감소 및 체중 감소에 우수한 효과를 나타냅니다.
비만증/체중 관리(Zepbound) : 최근 만성 체중 관리 적응증으로 승인되어 체중감량에서 전례 없는 임상결과를 얻으면서 빠르게 보급되고 있습니다.
심혈관 위험 감소 : 현재 진행 중인 임상시험에서 티르제파타이드의 심혈관 결과 개선에 대한 유용성을 평가하고 있으며, 이는 성장의 기폭제가 될 수 있습니다.
파이프라인 개발 : 비알코올성 지방간염(NASH), 폐쇄성 수면무호흡증, 좌심실 박출률 유지 심부전(HFpEF)을 대상으로 한 임상이 진행 중이며, 향후 확대가 기대됩니다.
3. 지리적 확장
티르제파타이드는 Mounjaro(당뇨병)와 Zepbound(비만)라는 브랜드명으로 전 세계적으로 출시되어 선진국과 신흥국 시장 모두에서 판매되고 있습니다.
아시아태평양은 비만 및 당뇨병 유병률 증가, 의료 접근성 향상, 새로운 체중 감량 솔루션에 대한 수요 증가로 인해 급성장할 것으로 예상됩니다.
Eli Lilly는 현재의 수급 불균형에 대응하기 위해 전 세계 제조 및 공급 능력을 크게 확장하고 있습니다.
4. 신규 적응증 승인
FDA와 EMA의 비만치료제(Zepbound) 승인으로 티르제파타이드의 치료 환경은 당뇨병 외의 질환으로 확대되었습니다.
심혈관계 결과 및 비만 관련 동반질환에 대한 승인이 예상되며, 그 위상은 더욱 높아질 것으로 보입니다.
여러 지역에서 진행 중인 승인 신청으로 보급이 가속화되고 수익원이 다양화될 것으로 예상됩니다.
5. 당뇨병과 비만증의 양호한 수량 모멘텀
Tirzepatide는 당뇨병과 비만증 모두에서 강력한 처방 증가를 보이고 있으며, 수요가 공급을 초과하는 경우가 많습니다.
2025년 업데이트는 비만 부문에서 지속적인 모멘텀을 강조하고 있으며, 티르제파타이드는 체중 관리 시장에서 핵심 치료제로 자리매김하고 있습니다.
실제 데이터는 임상시험 결과를 뒷받침하며, 광범위한 환자 집단에서 혈당 조절과 체중 감소가 지속적으로 개선되는 것을 보여줍니다.
6. 경쟁사와의 차별화와 시장 동향
티르제파타이드의 이중 GIP/GLP-1 기전은 혈당 조절과 체중 감소에 탁월한 효과를 보여 대사성 질환 관리의 새로운 벤치마킹 대상이 되고 있습니다.
주 1회 주사로 편리함을 제공하고, 기존 항당뇨병 요법에 비해 강력한 순응도를 지원합니다.
체중 감량에 대한 강력한 효과로 Ozempic, Wegovy와 차별화하여 대사 케어 시장에서의 경쟁을 강화합니다.
전 세계적인 비만 유행, 순환기 대사 치료에 대한 관심, 효과 높은 치료제에 대한 환자 선호 등 광범위한 시장 동향은 티르제파타이드의 성장 궤도를 강력하게 뒷받침하고 있습니다.
RWE(Real World Evidence)에 대한 신뢰가 높아짐에 따라 보험사의 신뢰가 강화되고, 상환이 향상되고, 접근성이 확대되고 있습니다.
Tirzepatide의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본) 시장을 조사 분석했으며, 매출 예측, 작용기전(MoA), 용법·용량, 연구개발(R&D)에 관한 정보를 전해드립니다.
목차
제1장 보고서 소개
제2장 Tirzepatide 개요 : 비만, 수면무호흡증, 2형 당뇨병 등의 승인된 적응증, 건선성 관절염, 1형 당뇨병 등의 잠재적 적응증
제품 상세
Tirzepatide 임상 개발
Tirzepatide 임상 연구
Tirzepatide 임상시험 정보
안전성과 유효성
기타 개발 활동
제품 프로파일
제3장 Tirzepatide 경쟁 구도(출시된 치료제)
제4장 경쟁 구도(후기 단계 신규 Tirzepatide 치료제)
제5장 Tirzepatide 시장 평가
승인된/잠재적 적응증에서 Tirzepatide 시장 전망
주요 7개 시장 분석
주요 7개 시장의 승인된/잠재적 적응증에 대한 Tirzepatide 시장 규모
시장 분석 : 국가별
미국의 승인된/잠재적 적응증에 대한 Tirzepatide 시장 규모
독일의 승인된/잠재적 적응증에 대한 Tirzepatide 시장 규모
영국의 승인된/잠재적 적응증에 대한 Tirzepatide 시장 규모
제6장 Tirzepatide SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 보고서 구입 옵션
KSM
영문 목차
영문목차
Key Factors Driving Tirzepatide Growth
1. Market Share Gains and New Patient Starts
Tirzepatide is rapidly capturing market share in both type 2 diabetes and obesity treatment, emerging as one of the most successful drug launches in recent years.
A significant surge in new patient starts is fueling strong prescription growth, with high demand from both diabetes and obesity care providers.
Eli Lilly's aggressive commercial strategy, strong physician education initiatives, and direct-to-consumer outreach are driving broad adoption across therapeutic segments.
2. Expansion Across Key Indications
Type 2 Diabetes (Mounjaro): Approved as a once-weekly injectable GLP-1/GIP dual agonist, showing superior efficacy in HbA1c reduction and weight loss compared to existing GLP-1 therapies.
Obesity/Weight Management (Zepbound): Recently approved for chronic weight management, with unprecedented clinical results in weight reduction driving rapid uptake.
Cardiovascular Risk Reduction: Ongoing trials are evaluating tirzepatide's benefits in cardiovascular outcomes, a potential growth catalyst.
Pipeline Developments: Studies in non-alcoholic steatohepatitis (NASH), obstructive sleep apnea, and heart failure with preserved ejection fraction (HFpEF) suggest significant future expansion opportunities.
3. Geographic Expansion
Tirzepatide is rolling out globally under the brands Mounjaro (diabetes) and Zepbound (obesity), with launches in both developed and emerging markets.
The Asia-Pacific region is expected to drive fast growth, fueled by rising obesity and diabetes prevalence, improved healthcare access, and strong demand for novel weight-loss solutions.
Eli Lilly is significantly expanding its global manufacturing and supply capacity to address ongoing demand-supply imbalances.
4. New Indication Approvals
FDA and EMA approvals for obesity (Zepbound) have broadened tirzepatide's treatment landscape beyond diabetes.
Anticipated approvals in cardiovascular outcomes and obesity-related comorbidities are expected to further enhance its positioning.
Ongoing regulatory submissions in multiple geographies will accelerate uptake and diversify revenue streams.
5. Strong Diabetes and Obesity Volume Momentum
Tirzepatide is demonstrating robust prescription growth in both diabetes and obesity, with demand often exceeding supply.
2025 updates highlight sustained momentum in the obesity segment, positioning tirzepatide as a cornerstone therapy in the weight management market.
Real-world data confirm clinical trial results, showing durable improvements in glycemic control and weight reduction across broad patient populations.
6. Competitive Differentiation and Market Trends
Tirzepatide's dual GIP/GLP-1 mechanism delivers superior efficacy in both glucose control and weight reduction, setting a new benchmark in metabolic disease management.
Once-weekly injection profile offers convenience and supports strong adherence compared to older antidiabetic regimens.
Its strong efficacy in weight loss differentiates it from Ozempic and Wegovy, intensifying competition in the metabolic care market.
Broader market trends such as the global obesity epidemic, cardiometabolic care focus, and patient preference for high-efficacy therapies strongly support tirzepatide's growth trajectory.
Increasing reliance on Real-World Evidence (RWE) is reinforcing payer confidence, improving reimbursement, and expanding access.
Tirzepatide Recent Developments
In September 2025, Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first Phase III trial to evaluate the safety and efficacy of MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both. At 30 weeks, MOUNJARO met the primary and all key secondary endpoints, achieving superior improvements in A1C and body mass index (BMI) compared to placebo. Results from the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and simultaneously published in The Lancet.
In July 2025, Eli Lilly and Company announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. In SURPASS-CVOT, MOUNJARO achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack or stroke vs. Trulicity.
"Tirzepatide Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Tirzepatide for approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus in the 7MM. A detailed picture of Tirzepatide's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Tirzepatide for approved and potential indications. The Tirzepatide market report provides insights about Tirzepatide's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Tirzepatide performance, future market assessments inclusive of the Tirzepatide market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Tirzepatide sales forecasts, along with factors driving its market.
Tirzepatide Drug Summary
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) dual receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Tirzepatide lowers fasting and postprandial glucose, increases insulin sensitivity, decreases food intake and reduces body weight in patients with type 2 diabetes. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing.
Tirzepatide has been approved by the US FDA as MOUNJARO for adults with type 2 diabetes to improve glycemic control, and as ZEPBOUND for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, ZEPBOUND is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide is also approved as MOUNJARO in some countries outside the US for adults with type 2 diabetes, obesity or those who are overweight who also have a weight-related comorbid condition. Both MOUNJARO and ZEPBOUND should be used in combination with diet and exercise. The report provides Tirzepatide's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Tirzepatide is in the Phase III stage of clinical development for the treatment of patients with Psoriatic arthritis (NCT06588296) and Type 1 diabetes mellitus (NCT06914895).
Scope of the Tirzepatide Market Report
The report provides insights into:
A comprehensive product overview including the Tirzepatide MoA, description, dosage and administration, research and development activities in approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus.
Elaborated details on Tirzepatide regulatory milestones and other development activities have been provided in Tirzepatide market report.
The report also highlights Tirzepatide's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The Tirzepatide market report also covers the patents information, generic entry and impact on cost cut.
The Tirzepatide market report contains current and forecasted Tirzepatide sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Tirzepatide market report also features the SWOT analysis with analyst views for Tirzepatide in approved and potential indications.
Methodology:
The Tirzepatide market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Tirzepatide Analytical Perspective by DelveInsight
In-depth Tirzepatide Market Assessment
This Tirzepatide sales market forecast report provides a detailed market assessment of Tirzepatide for approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Tirzepatide sales data uptil 2034.
Tirzepatide Clinical Assessment
The Tirzepatide market report provides the clinical trials information of Tirzepatide for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Tirzepatide Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Tirzepatide Market Potential & Revenue Forecast
Projected market size for the Tirzepatide and its key indications
Commercial partnerships, licensing deals, and M&A activity
Tirzepatide Clinical Differentiation
Tirzepatide Efficacy & safety advantages over existing drugs
Tirzepatide Unique selling points
Tirzepatide Market Report Highlights
In the coming years, the Tirzepatide market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Tirzepatide companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tirzepatide's dominance.
Other emerging products for Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus are expected to give tough market competition to Tirzepatide and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tirzepatide in approved and potential indications.
Analyse Tirzepatide cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Tirzepatide sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Tirzepatide in approved and potential indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of Tirzepatide? How strong is Tirzepatide's clinical and commercial performance?
What is Tirzepatide's clinical trial status in each individual indications such as Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tirzepatide Manufacturers?
What are the key designations that have been granted to Tirzepatide for approved and potential indications? How are they going to impact Tirzepatide's penetration in various geographies?
What is the current and forecasted Tirzepatide market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Tirzepatide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Tirzepatide for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is Tirzepatide? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. Tirzepatide Overview in approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus
